Literature DB >> 22004903

Autoimmune mediated regulation of ovarian tumor growth.

Cengiz Z Altuntas1, Ritika Jaini, Pavani Kesaraju, Daniel Jane-wit, Justin M Johnson, Kelly Covey, Christopher A Flask, Martin Dutertre, Jean-Yves Picard, Vincent K Tuohy.   

Abstract

OBJECTIVES: An immune response sufficient to induce organ failure may provide protection and therapy against tumors derived from the targeted organ particularly when removal or ablation of the organ is part of the standard therapy and does not threaten survival. We have previously shown that a targeted immune response directed against the ovarian-specific protein, inhibin-α, causes ovarian failure. Here we determined whether inhibin-α autoimmunity is effective in both prevention and treatment of ovarian tumors.
METHODS: A transgene consisting of the SV40 large tumor transformation antigen under the regulation of an anti-Mullerian hormone promoter (AMH-SV40Tag) was transferred by backcrossing for 12 generations to SJL/J mice producing SJL.AMH-SV40Tag (H-2(s)) females that develop a high incidence of autochthonous granulosa cell tumors. We determined whether immunization of SJL.AMH-SV40Tag female mice with the IA(s)-restricted p215-234 peptide of mouse inhibin-α was capable of preventing and treating these ovarian tumors.
RESULTS: The growth of autochthonous ovarian granulosa cell tumors in SJL.AMH-SV40Tag transgenic mice was significantly inhibited in mice immunized with Inα 215-234. In addition, significant inhibition of tumor growth occurred when mice with established ovarian granulosa cell tumors were therapeutically vaccinated with Inα 215-234.
CONCLUSIONS: Our results indicate that induction of ovarian-specific autoimmunity may serve as an effective way to prevent the emergence of autochthonous ovarian tumors and control the growth of established ovarian malignancies.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22004903      PMCID: PMC3258506          DOI: 10.1016/j.ygyno.2011.09.023

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  28 in total

1.  Cancer Vaccine Collaborative 2002: opening address.

Authors:  Lloyd J Old
Journal:  Cancer Immun       Date:  2003-02-06

Review 2.  Regulatory T cells in ovarian cancer: biology and therapeutic potential.

Authors:  Brian Barnett; Ilona Kryczek; Pui Cheng; Weiping Zou; Tyler J Curiel
Journal:  Am J Reprod Immunol       Date:  2005-12       Impact factor: 3.886

Review 3.  Understanding crypticity is the key to revealing the pathogenesis of autoimmunity.

Authors:  Kamal D Moudgil; Eli E Sercarz
Journal:  Trends Immunol       Date:  2005-07       Impact factor: 16.687

4.  T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.

Authors:  A L Marzo; R A Lake; B W Robinson; B Scott
Journal:  Cancer Res       Date:  1999-03-01       Impact factor: 12.701

5.  Autoimmune targeted disruption of the pituitary-ovarian axis causes premature ovarian failure.

Authors:  Cengiz Z Altuntas; Justin M Johnson; Vincent K Tuohy
Journal:  J Immunol       Date:  2006-08-01       Impact factor: 5.422

Review 6.  The B7 family and cancer therapy: costimulation and coinhibition.

Authors:  Xingxing Zang; James P Allison
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

7.  Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay.

Authors:  N P Groome; P J Illingworth; M O'Brien; I Cooke; T S Ganesan; D T Baird; A S McNeilly
Journal:  Clin Endocrinol (Oxf)       Date:  1994-06       Impact factor: 3.478

Review 8.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

Authors:  Y Kawakami; S Eliyahu; C H Delgado; P F Robbins; L Rivoltini; S L Topalian; T Miki; S A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

10.  Clonal deletion of thymocytes can occur in the cortex with no involvement of the medulla.

Authors:  Tom M McCaughtry; Troy A Baldwin; Matthew S Wilken; Kristin A Hogquist
Journal:  J Exp Med       Date:  2008-10-20       Impact factor: 14.307

View more
  3 in total

1.  Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.

Authors:  Allan NoeDominguez-Romero; Rubén Zamora-Alvarado; Rodolfo Servín-Blanco; Erendira G Pérez-Hernández; Laura E Castrillon-Rivera; Maria Elena Munguia; Gonzalo Acero; Tzipe Govezensky; Goar Gevorkian; Karen Manoutcharian
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Vaccination with inhibin-α provides effective immunotherapy against testicular stromal cell tumors.

Authors:  Robert Aguilar; Justin M Johnson; Patrick Barrett; Vincent K Tuohy
Journal:  J Immunother Cancer       Date:  2017-04-18       Impact factor: 13.751

3.  Sialyl-tn in cancer: (how) did we miss the target?

Authors:  Sylvain Julien; Paula A Videira; Philippe Delannoy
Journal:  Biomolecules       Date:  2012-10-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.